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Background and Aims: Colorectal cancer (CRC) is largely preventable with routine screening and surveillance
colonoscopy; however, interval cancers arising from precancerous lesions missed by standard colonoscopy still
occur. An increased adenoma detection rate (ADR) has been found to be inversely associated with interval can-
cers. The G-EYE device includes a reusable balloon integrated at the distal tip of a standard colonoscope, which
flattens haustral folds, centralizes the colonoscope’s optics, and reduces bowel slippage. The insufflated balloon
also aims to enhance visualization of the colon during withdrawal, thereby increasing the ADR.
Methods: In this randomized, controlled, international, multicenter study (11 centers), patients (aged 50 years)
referred to colonoscopy for screening, surveillance, or changes in bowel habits were randomized to undergo
either balloon-assisted colonoscopy by using an insufflated balloon during withdrawal or standard high-
definition colonoscopy. The primary endpoint was the ADR.
Results: One thousand patients were enrolled between May 2014 and September 2016 to undergo colonoscopy
by experienced endoscopists; 803 were finally analyzed (standard colonoscopy nZ 396; balloon-assisted colonos-
copy nZ 407). Baseline parameters were similar in both groups. Balloon-assisted colonoscopy provided a 48.0%
ADR compared with 37.5% in the standard colonoscopy group (28% increase; P Z .0027). Additionally, balloon-
assisted colonoscopy provided for a significant increase in detection of advanced (P Z .0033) flat adenomas
(P < .0001) and sessile serrated adenomas/polyps (P Z .0026).
Conclusion: Balloon-assisted colonoscopy yielded a higher ADR and increased the detection of advanced, flat,
and sessile serrated adenomas/polyps when compared with standard colonoscopy. Improved detection by the G-
EYE device could impact the quality of CRC screening by reducing miss rates and consequently reducing interval
cancer incidence. (Clinical trial registration number: NCT01917513.) (Gastrointest Endosc 2019;89:545-53.)
(footnotes appear on last page of article)
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Colorectal cancer (CRC) is the second-most lethal can-
cer in the United States, with an annual incidence of
approximately 140,000 cases and 50,000 CRC-related
deaths.1-3 Although fatal in its advanced stages, it is, by
far, the most preventable cancer when detected at an
early stage, in the form of pre-cancerous lesions.2
The valuable contribution of colonoscopy to the
prevention of CRC is ascribed to the early detection and
removal of precancerous colon polyps, most frequently
adenomas.4,5 The adenoma detection rate (ADR), defined
as the percentage of screened patients in whom at least 1
adenoma is found, has become one of the most important
quality indicators for colonoscopy. Indeed, in a large,
multicenter study evaluating the association between
ADR and the risk of CRC diagnosed 6 months to 10 years
after colonoscopy, ADR was inversely related to the risk of
interval CRC, as manifested by a 3.0% decrease in risk of
CRC with each 1.0% increase in the ADR.6 The U.S. Multi-
Society Task Force on Colorectal cancer established target
ADRs of >30% for men and >20% for women undergoing
screening colonoscopy.7 The European Society of
Gastrointestinal Endoscopy and the United European
Gastroenterology established a minimum ADR standard
of 25%.8
Back-to-back studies comparing 2 standard colonoscopy
procedures have indicated that 20% to 22% of adenomas
are still missed,9,10 whereas similarly designed studies
comparing standard colonoscopy with optical or mechanical
enhancement technologies for improved polyp detection re-
ported adenoma miss rates by standard colonoscopy be-
tween 41% and 48.3%.11-13 The marked miss rates
associated with current technologies are commonly attrib-
uted to the location of polyps on the proximal aspects of co-
lon folds and flexures, along with their flat morphology.14,15
Furthermore, studies have indicated that colonoscopy is
less effective in preventing CRC in the proximal colon
compared with the distal colon,16-18 possibly because of the
higher prevalence of serrated, flat, and depressed lesions
featuring a relatively subtle appearance within the proximal
colon.19-21
The G-EYE (Smart Medical Systems Ltd, Ra’anana,
Israel) is a novel device designed to mechanically enhance
the detection of polyps during colonoscopy. It comprises a
reusable balloon integrated on a conventional colonoscope
(Fig. 1). The balloon does not alter the mechanics or the
technical performance of the colonoscope. After cecal
intubation, the colonoscope is withdrawn with the
balloon partially inflated, thereby straightening colon
folds, centralizing the colonoscope’s optics, and reducing
bowel slippage. The G-EYE device has demonstrated
safety and efficacy in previous clinical studies.12,22 The cur-
rent randomized, controlled study aimed to directly
compare the G-EYE colonoscopy ADR with that of standard
high-definition colonoscopy.
MATERIALS AND METHODS
Study design
This study was a randomized, 2-arm, multicenter study.
The study received institutional review board approval at
each participating site and was registered at clinicaltrials.
gov (NCT01917513). Patients scheduled for colonoscopy
were randomized to undergo either standard colonoscopy
or balloon-assisted colonoscopy by using the G-EYE de-
vice. All colonoscopes used were high-definition endo-
scopes of the same brand and series (Pentax EC-3890i,
Pentax, Tokyo, Japan), to eliminate endoscope and
optics-related bias. iScan1 was applied during withdrawal
of the colonoscope, in both study groups. The study
involved 45 experienced endoscopists (most endoscopists
had experience of >2500 colonoscopic procedures) from
11 medical centers in Europe, Israel, and India. Physicians
with no prior experience with the G-EYE first underwent
technical training. Consent was obtained from all study pa-
tients. Bowel preparation was performed according to the
standard guidelines of each center and was graded accord-
ing to the Boston Bowel Preparation Quality Scale.23
Conscious sedation was used (mostly midazolam,
fentanyl, propofol, or a combination thereof, according
to the center’s preference). Device insertion time, net
withdrawal time (without intervention time), and total
procedure time were measured and recorded.
All detected polyps, except for rectal lesions with endo-
scopic features of hyperplastic pathology, measuring 2 mm
or greater, were endoscopically removed or biopsies and
subjected to histologic evaluation. Polyps were classified
by size (diminutive, 2-5 mm; small, 6-9 mm or
large, 10 mm), by location, and according to Paris and
Kudo classifications.24,25 The polyp detection rate was
defined as the percentage of patients in whom at least 1
polyp was found. The ADR was defined as the percentage
of patients in whom at least 1 adenoma was found. An ad-
enoma was defined as an adenoma and/or sessile serrated
adenoma/polyp or traditional serrated adenoma. Advanced
adenomas were defined as adenomas that were
either 10 mm in diameter, included a villous component,
harbored high-grade dysplasia, or were cancerous. The
proximal colon was defined as the transverse colon, hepat-
ic flexure, ascending colon, and cecum. Safety parameters
and adverse events were assessed during the procedure
and by phone call interview during the 48 to 72-hour post-
procedural follow-up period.
Participants
Patients aged 50 years and older undergoing colonos-
copy for screening or after a positive result on a fecal
occult blood test, for polyp surveillance, or to assess
changes in bowel habits, were recruited to the study.
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Exclusion criteria included previous colon surgery (except
for appendectomy), known inflammatory bowel disease,
polyposis, suspected colon stricture, diverticulitis or toxic
megacolon, a history of radiation therapy to the abdomen
or pelvis, pregnancy or lactation, current enrollment in
another clinical study, routine use of anticoagulants, and
history of coronary ischemia or cardiovascular event within
3 months before the procedure. Patients were withdrawn
from the study in cases of inadequate bowel preparation
(score <2 in 1 or more colon segments, according to the
Boston Bowel Preparation Quality Scale), technical error
or device malfunction, non-compliance with the protocol,
screening failure, occurrence of serious adverse events or
any medical condition revealed during the examination
that required cessation of treatment for medical reasons
or that may affect the study outcome.
The G-EYE device
The G-EYE is a reusable balloon, integrated onto a stan-
dard colonoscope (any brand and model can be used)
(Fig. 1). The G-EYE uses a standard interface and standard
video processor and can be disinfected by using a regular
reprocessing protocol. The balloon is inflated by a
dedicated inflation system (NaviAid SPARK2C, Smart
Medical Systems Ltd) that provides, aside from anchoring
pressure, 3 levels of partial, lower, and non-anchoring pres-
sure to the balloon, applied during withdrawal of the colon-
oscope (Video 1, available online at www.giejournal.org).
The G-EYE is inserted until cecal intubation, with the
balloon deflated. Once the cecum is reached and
inspected, the balloon is inflated to partial pressure. The
G-EYE device is withdrawn with the balloon inflated,
eliciting colon fold flattening, optical image centralization,
and reduced bowel slippage during withdrawal. The fold-
flattening effect of the G-EYE brings mucosal surfaces nor-
mally located behind haustral folds into the colonoscope’s
field of view (Fig. 2, Video 2, available online at www.
giejournal.org), enabling immediate and straightforward
removal of detected polyps. Additionally, during
polypectomy, the balloon can be inflated to anchoring
pressure, thereby stabilizing the colonoscope and
facilitating controlled intervention.
Study endpoints
The primary endpoint of the study was the ADR in each
group (G-EYE vs standard colonoscopy). Secondary end-
points included the number, location, and type of polyps
and adenomas detected, procedure times, and safety
parameters.
Randomization and blinding
Patients were randomized to the G-EYE or the standard
colonoscopy group, in a 1:1 allocation ratio based on
randomization scheme blocks, stratified by center, via a
computer-generated randomization scheme created with
SAS version 9.4 statistical software (SAS Institute, Cary,
NC). Physicians were not blinded to the outcome of the
randomization; however, physicians were assigned to pa-
tients before randomization.
Statistical methods
Sample size calculation: The primary outcome measure
of the study was the ADR of G-EYE versus standard high-
definition colonoscopy. The null hypothesis was that the
ADR is equal in both groups. Based on the medical litera-
ture, we assumed an ADR baseline of 24%26 and
calculated that to achieve a 35% increase in the detection
rate, with 80% power at a 5% level of significance, 450
patients were required per study group, requiring a total
sample size of 900 patients. Assuming a 10% dropout
rate, 1000 patients were recruited for the study.
Analysis methods
Continuous variables were summarized by the mean
and standard deviation and compared with a 2-sample
t test or the Wilcoxon rank sum test, as appropriate. Cate-
gorical data were summarized by a count and percentage
and compared by using the chi-square test. Polyp, ade-
noma, sessile serrated adenomas/polyps, serrated lesions,
and flat lesions detection rate were presented in percent-
age and compared by using the chi-square test. The ADR
also was presented by indication for colonoscopy. Count
data, such as number of polyps or adenomas detected,
were compared by using Poisson regression models.
Figure 1. G-EYE system. A, G-EYE balloon integrated on a standard colonoscope. B, NaviAid SPARK2C inflation system.
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Statistical analyses were performed with SAS V9.4 (SAS
Institute). A P value of .05 or lower was considered statis-
tically significant. Nominal P values are presented.
RESULTS
From May 2014 to September 2016, 1000 patients were
enrolled into the study. Of these 1000 patients, 502 were
randomized to the balloon-assisted colonoscopy group,
and 498 were randomized to the standard colonoscopy
group. Results of 396 and 407 patients were analyzed in
the standard colonoscopy and G-EYE groups, respectively
(Fig. 3). Reasons for exclusion were similar between the
2 groups and are shown in Figure 3. Baseline measures,
indications for colonoscopy, and Boston Bowel
Preparation Quality Scale scores in both groups were
similar and are presented in Table 1. Distribution of
experienced and non-experienced physicians between
the 2 study groups was similar (Table 1).
Balloon-assisted colonoscopy provided a significant in-
crease in the ADR when compared with standard colonos-
copy, with an ADR of 48.0% recorded in the former and
37.5% in the latter cohort (P Z .0027) (Table 2) (primary
endpoint). A similar increment in detection efficacy was
observed between balloon-assisted colonoscopy and stan-
dard colonoscopy-detected polyps, as manifested by a
polyp detection rate of 59.0% in the balloon-assisted colo-
noscopy arm and 47.7% in the standard colonoscopy arm
(P Z .0014) (Table 2). In line with these findings,
balloon-assisted colonoscopy detected a mean of 1.00 ade-
noma per patient, whereas standard colonoscopy detected
a mean of 0.68 adenomas per patient (P < .0001; 47.1% in-
crease). Moreover, balloon-assisted colonoscopy detected
a higher number of diminutive and small adenomas
compared with standard colonoscopy, with 245 versus
160 diminutive adenomas (P < .0001; 53.1% increase)
and 75 versus 54 small adenomas (P Z .0946; 38.9% in-
crease), respectively. In addition, the number of large (86
vs 52) and advanced (109 vs 67) adenomas was higher in
the balloon-assisted versus standard colonoscopy groups,
respectively, representing an increase of 62.3% (P Z
.0093) in large-size adenomas and a 62.7% (P Z .0033) in-
crease in advanced adenomas. Further, an increase in the
number of flat adenomas and sessile serrated adenomas/
polyps in the balloon-assisted colonoscopy arm was seen,
with 85 and 20, respectively, compared with 35 and 3,
respectively, in the standard colonoscopy arm (represent-
ing an increase of 142.9% [P < .0001] and 566.7% [P Z
.0026], respectively). An even larger difference in the num-
ber of flat and serrated adenomas/polyps was detected in
the proximal colon, with 65 and 17, respectively, detected
by balloon-assisted colonoscopy compared with 21 and 2
detected, respectively, by standard colonoscopy (repre-
senting an increase of 209.5% [P < .0001] and 750%
[PZ .0048], respectively). Higher detection rates of sessile
Figure 2. A, Transverse colon without balloon insufflation. B, Transverse colon with balloon insufflation. C, Sigmoid passage with balloon insufflation.
D, Diagnosis of a serrated adenoma.
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serrated adenomas/polyps (2.7%), serrated lesions (14.1%),
and flat adenomas (14.9%) by balloon-assisted colonos-
copy as compared with the standard colonoscopy group
(0.8%, 11.2%, and 6.9%, respectively) also was observed
(Table 2). The ADR per each indication for colonoscopy
(screening, surveillance, change in bowel habits, and
positive fecal occult blood test) presented an increase in
the balloon-assisted colonoscopy arm versus standard colo-
noscopy (P Z .0165; P Z .4382; P Z .3882; P Z .1319,
respectively) (Table 2). The ADR of balloon-assisted colo-
noscopy performed by physicians having prior experience
with the G-EYE device was similar to that of physicians with
no prior experience (49.0% vs 47.2%; P Z .7193). The
balloon-assisted colonoscopy ADRs in the initial part and
final part of the study were similard48.6% and 47.1%,
respectively (P Z .8657). Total procedure time of
balloon-assisted colonoscopy was approximately 3 minutes
longer compared with standard colonoscopy, because of
the higher rate of endoscopic interventions consequential
of the higher ADR (Table 1). Two serious adverse events
were reported in the balloon-assisted colonoscopy arm,
both of which occurred before balloon inflation. In the first
patient, the colonoscopy procedure was prematurely
terminated because of inappropriate bowel preparation.
A day later, the patient was diagnosed with an obstructive
sigmoid tumor, underwent surgery, and died a few days af-
ter as a result of aspiration. In the second case, the patient
had an irregular heart rate and bradycardia before the initi-
ation of the procedure. This patient did not undergo colo-
noscopy and was instead admitted for 24 hours of cardiac
Excluded (n=13)
•  Not meeting inclusion criteria (n=13)
Randomized (n=1000)
Allocated to intervention
Standard Colonoscopy (n=498)
•  Received allocated intervention (n=492)
•  Did not receive allocated intervention:     
Endoscope availability (n=4)
Technical problem (n=2)
Screening failure (n=0)
Medical conditions (n=0)
SAE (n=0)
Allocated to intervention
Endoscope availability (n=8)
Technical problem (n=1)
Screening failure (n=2)
Medical conditions (n=1)
SAE (n=1)
Analyzed (n=396) Analyzed (n=407)
•  Excluded from analysis :
Inadequate bowl preparation (n=41)
Medical condition (n=25)
Protocol violation (n=11)
Screening failure (n=4)
Technical problem (n=1)
•  Excluded from analysis :
Inadequate bowl preparation (n=48)
Medical condition (n=18)
Protocol violation (n=24)
Screening failure (n=6)
Technical problem (n=2)
Balloon-Assisted Colonoscopy  (n=502)
•  Received allocated intervention (n=489)
•  Did not receive allocated intervention:
Assessed for eligibility (n=1013)
Enrollment
Analysis
Allocation
Figure 3. CONSORT flow chart, enrollment, allocation, analysis of study participants and serious adverse events.
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monitoring and was released the next day with no addi-
tional complaints.
DISCUSSION
Screening colonoscopy is strongly associated with
reduced CRC incidence and mortality; however, the ade-
noma miss rate remains a concern.27 A population-based
study reported a 6% interval cancer rate after negative co-
lonoscopy results in CRC patients.28 A large-scale study
correlating quality indicators in colonoscopy and interval
cancer risk concluded that the endoscopist ADR is a prin-
cipal predictor for the risk of interval cancer after screening
colonoscopy.29 International efforts have resulted in local
screening programs for increasing awareness and quality
of CRC screening and monitoring the endoscopist ADR.
In addition, novel mechanical (eg, Endocuff, Arc Medical
Design Ltd, Leeds, UK) and optical technologies
(eg, FUSE, EndoChoice, Alpharetta, Ga) have been
introduced recently to increase the ADR and to reduce
interval cancer rates. However, these technologies
showed no consistent increased efficacy in large
randomized trials.30-35 The current randomized study
demonstrated a significant increase in the ADR by
balloon-assisted colonoscopy compared with standard co-
lonoscopy. The ADR in the standard colonoscopy group
was 37.5%, which exceeds the recommended threshold
of 30%.7 However, use of the insufflated balloon during
withdrawal increased the ADR to 48.0%. In addition,
balloon-assisted colonoscopy significantly improved the
per-patient ADR (1.00 adenoma per patient), both in com-
parison to the standard colonoscopy group (0.68 adenoma
per patient) and relative to published studies reporting a
range of 0.42 to 0.5 adenoma per patient.33,36 Because cur-
rent U.S. and European Union surveillance guidelines
define surveillance intervals by the number of adenomas
detected in a single patient,4,37 this will have direct implica-
tions for patient surveillance intervals. A recent study sug-
gested that use of behind-folds visualizing colonoscopy
technologies had no advantage in the detection of
advanced and large adenomas (10 mm).38 However, in
the present study, the number of large and advanced
adenomas detected by balloon-assisted colonoscopy was
substantially higher (62.3% and 62.7% increase, respec-
tively), compared with standard colonoscopy. This sug-
gests that in previous studies, some advanced lesions
were missed, notwithstanding the use of behind-folds visu-
alizing techniques. The G-EYE device seems therefore the
first technology that has the potential to increase the gen-
eral ADR and advanced ADR, in particular. Studies have
shown a strong correlation between lesion size and its ma-
lignancy potential, with larger lesions considered to be at
higher risk for submucosal invasion and lymph node
TABLE 1. Baseline parameters, indications for colonoscopy, and procedure times by type of colonoscopy
Baseline characteristics Standard colonoscopy G-EYE P value
Age, mean, y 65.2 65.4 .6708*
Sex, % female 43.7 50.1 .0677y
BBPS score, mean  SD
Global 2.57  0.42 2.56  0.42 .7854*
Descending colon 2.62  0.49 2.61  0.49 .8412*
Transverse colon 2.62  0.49 2.62  0.49 .8377*
Ascending colon 2.47  0.50 2.46  0.50 .7701*
Indication for colonoscopy, no. (%) .8488y
Screening 163 (41.2) 165 (40.5)
Surveillance 76 (19.2) 82 (20.1)
Change in bowel habits 61 (15.4) 55 (13.5)
Positive result on fecal occult blood test 96 (24.2) 105 (25.8)
Endoscopist level of endoscopic experience, no. (%) .3747y
800-2500 procedures 55 (53.4) 48 (46.6)
>2500 procedures 341 (48.7) 359 (51.3)
Procedure time, mean  SD, min
Insertion time 8.19  4.83 7.92  4.83 .4935z
Withdrawal time 7.09  1.37 7.33  1.64 .0157z
Total procedure time 22.15  10.13 24.93  11.41 < .0001z
BBPS, Boston Bowel Preparation Quality Scale; SD, standard deviation.
*t test.
yChi-square.
zKruskal-Wallis.
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involvement.39 Therefore, detection and removal of such
lesions and proper determination of surveillance intervals
are critical to CRC prevention.4,5 The increased rate in
detection of advanced adenomas may theoretically repre-
sent the risk reduction of advanced adenomas developing
into CRC and thus of interval cancer reduction.
Detection rates of sessile serrated adenomas\polyps,
serrated lesions, and flat adenomas were higher in the
G-EYE group, compared with standard colonoscopy (2.7%,
14.1%, and 14.9% compared with 0.8%, 11.2%, and 6.9%,
respectively). In a multicenter study involving 2167 patients
evaluating segmental ADR and sessile serrated adenoma\po-
lyp detection rates in average-risk patients, sessile serrated
adenoma\polyp detection rates were reported to be 2%,
which is lower than the sessile serrated adenoma\polyp
detection rates reported in the G-EYE group.40 In a
retrospective analysis of screening colonoscopy with high-
definition plus iScan, serrated lesion detection rates and
flat adenoma detection rates were reported to be 10%,
demonstrating the superiority of G-EYE.41 Interestingly, a
recently published study highlighted the strong
overrepresentation of interval cancers in the ascending
colon and cecum after negative results on colonoscopies
performed less than 3 years before the diagnosis of CRC.42
Flat and serrated lesions are typically difficult to detect
during colonoscopy and are known to be more common
in the proximal colon.20 These lesions are often missed
because of their flat architecture and pale appearance.19-21,43
TABLE 2. PDR, ADR, and adenoma characterization by type of colonoscopy
Standard
colonoscopy G-EYE % Difference P value
PDR/ADR and adenoma per patient
PDR 47.7% 59.0% 23.7% .0014*
ADR 37.5% 48.0% 28.0% .0027*
Polyps per patient 0.97 1.42 46.4% < .0001y
Adenomas per patient 0.68 1.00 47.1% < .0001y
ADR per indication for colonoscopy
Screening 30.3% 43.0% 41.9% .0165*
Surveillance 51.3% 57.5% 12.1% .4382*
Change in bowel habits 30.5% 38.2% 25.2% .3882*
Positive fecal occult blood test result 43.2% 53.9% 24.8% .1319*
Adenoma, distribution according to size, no. (average per patient)
Diminutive (2-5 mm) 160 (0.41) 245 (0.61) 53.1% < .0001y
Small (6-9 mm) 54 (0.14) 75 (0.19) 38.9% .0946y
Large (10 mm) 53 (0.14) 86 (0.21) 62.3% .0093y
Adenoma characterization, no. (average per patient)
Advanced adenomas 67 (0.17) 109 (0.27) 62.7% .0033y
Non-advanced adenomas 200 (0.51) 297 (0.74) 48.5% < .0001y
Serrated lesions 59 (0.15) 90 (0.22) 52.5% .0192y
SSAs/Ps 3 (0.01) 20 (0.05) 566.7% .0026y
Hyperplastic polyps 53 (0.14) 67 (0.17) 26.4% .2665y
Traditional serrated adenomas 3 (0.01) 3 (0.01) 0% .9705y
Flat adenomas 35 (0.09) 85 (0.21) 142.9% < .0001y
SSA/P, serrated lesion, and flat lesion detection rates
SSA/P detection rate 0.8% 2.7% 237.5% .0357*
Serrated lesion detection rate 11.2% 14.1% 25.9% .2216*
Flat lesion detection rate 6.9% 14.9% 116.0% .0003*
Adenoma characterization in the right side of
the colon, no. (average per patient)
Flat adenoma 21 (0.05) 65 (0.16) 209.5% < .0001y
SSA/P 2 (0.01) 17 (0.04) 750.0% .0048y
PDR, Polyp detection rate; ADR, adenoma detection rate; SSA/P, sessile serrated adenoma\polyp.
*Chi-square.
yPoisson model.
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United States and European Union guidelines also provide
recommendations regarding the appropriate surveillance
interval in the event that such lesions are detected during
colonoscopy.4,37 In the present study, the G-EYE detected
significantly more flat adenomas and sessile serrated ad-
enomas\polyps in the proximal colon (Table 2). The
G-EYE device fold-flattening effect likely enabled exposure
of these otherwise hidden lesions, thus demonstrating that
this technology both increases general detection efficacy
and specifically enables detection of clinically significant le-
sions that have a direct effect on CRC prevention. The
similar balloon-assisted colonoscopy ADR in the initial
and final parts of the study may suggest that there is no
learning curve associated with the G-EYE device. However,
our study was not designed to evaluate the G-EYE learning
curve, and additional studies are needed to further estab-
lish this point.
This study had several limitations. First, the recruitment
rate per sitewas not equal. Second, the number of procedures
performed by each endoscopist was not evenly distributed;
endoscopists participated as per on-site availability. Third,
the dropout rate was higher than expected, mostly because
of insufficient bowel preparation required to maintain high-
quality examination. Nevertheless, the outcomes were signifi-
cant. Fourth, endoscopists were not blinded to the results of
randomization. Fifth, the study population included patients
with positive results on fecal occult blood tests, for whom
baseline ADR is usually higher than in the general screening
population. The randomized and international design of this
study provides an enhanced attribute to the described results.
In summary, this study showed that the G-EYE device de-
tects considerably more adenomas than does standard colo-
noscopy, thereby potentially reducing colonoscopy miss
rates, with no significant increase in procedural time. Based
on our experience, the G-EYE device does not alter the me-
chanical properties of the colonoscope. The improved ADR,
increased number of adenomas per patient, and higher inci-
denceof detectedadvanced, large,flat, and sessile serratedad-
enomas\polyps may all have clinical implications in reducing
the rate of interval cancer. This new technology has the poten-
tial to increase the standard of care in CRC prevention.
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